| Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 X Deng, N Dzamko, A Prescott, P Davies, Q Liu, Q Yang, JD Lee, ... Nature chemical biology 7 (4), 203-205, 2011 | 500 | 2011 |
| 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization RJ Nichols, N Dzamko, NA Morrice, DG Campbell, M Deak, A Ordureau, ... Biochemical Journal 430 (3), 393-404, 2010 | 463 | 2010 |
| Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization N Dzamko, M Deak, F Hentati, AD Reith, AR Prescott, DR Alessi, ... Biochemical Journal 430 (3), 405-413, 2010 | 444 | 2010 |
| CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK MJ Watt, N Dzamko, WG Thomas, S Rose-John, M Ernst, D Carling, ... Nature medicine 12 (5), 541-548, 2006 | 320 | 2006 |
| Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology N Dzamko, A Gysbers, G Perera, A Bahar, A Shankar, J Gao, YH Fu, ... Acta neuropathologica 133 (2), 303-319, 2017 | 301 | 2017 |
| The IkappaB kinase family phosphorylates the Parkinson’s disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling N Dzamko, F Inesta-Vaquera, J Zhang, C Xie, H Cai, S Arthur, L Tan, ... PloS one 7 (6), e39132, 2012 | 253 | 2012 |
| Inflammation is genetically implicated in Parkinson’s disease N Dzamko, CL Geczy, GM Halliday Neuroscience 302, 89-102, 2015 | 247 | 2015 |
| Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease RJ Nichols, N Dzamko, JE Hutti, LC Cantley, M Deak, J Moran, ... Biochemical Journal 424 (1), 47-60, 2009 | 245 | 2009 |
| AMPK β1 deletion reduces appetite, preventing obesity and hepatic insulin resistance N Dzamko, BJW van Denderen, AL Hevener, SB Jørgensen, J Honeyman, ... Journal of Biological Chemistry 285 (1), 115-122, 2010 | 218 | 2010 |
| Whole body deletion of AMP-activated protein kinase β2 reduces muscle AMPK activity and exercise capacity GR Steinberg, HM O'Neill, NL Dzamko, S Galic, T Naim, R Koopman, ... Journal of Biological Chemistry 285 (48), 37198-37209, 2010 | 195 | 2010 |
| AMPK‐independent pathways regulate skeletal muscle fatty acid oxidation N Dzamko, JD Schertzer, JG Ryall, R Steel, SL Macaulay, S Wee, ... The Journal of physiology 586 (23), 5819-5831, 2008 | 182 | 2008 |
| Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin JM Ye, N Dzamko, ME Cleasby, BD Hegarty, SM Furler, GJ Cooney, ... Diabetologia 47 (7), 1306-1313, 2004 | 161 | 2004 |
| Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease J Galper, NJ Dean, R Pickford, SJG Lewis, GM Halliday, WS Kim, ... Brain 145 (10), 3472-3487, 2022 | 135 | 2022 |
| Parkinson’s progression prediction using machine learning and serum cytokines D Ahmadi Rastegar, N Ho, GM Halliday, N Dzamko NPJ Parkinson's disease 5 (1), 14, 2019 | 130 | 2019 |
| Liver‐specific suppressor of cytokine signaling‐3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity 1 N Sachithanandan, BC Fam, S Fynch, N Dzamko, MJ Watt, S Wormald, ... Hepatology 52 (5), 1632-1642, 2010 | 129 | 2010 |
| AMPK‐dependent hormonal regulation of whole‐body energy metabolism NL Dzamko, GR Steinberg Acta physiologica 196 (1), 115-127, 2009 | 128 | 2009 |
| Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease F Atashrazm, D Hammond, G Perera, C Dobson-Stone, N Mueller, ... Scientific reports 8 (1), 15446, 2018 | 125 | 2018 |
| Autophagy activation promotes clearance of α-synuclein inclusions in fibril-seeded human neural cells J Gao, G Perera, M Bhadbhade, GM Halliday, N Dzamko Journal of Biological Chemistry 294 (39), 14241-14256, 2019 | 121 | 2019 |
| Increased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers N Dzamko, DB Rowe, GM Halliday Movement Disorders 31 (6), 889-897, 2016 | 120 | 2016 |
| LRRK2‐mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients F Atashrazm, D Hammond, G Perera, MF Bolliger, E Matar, GM Halliday, ... Movement disorders 34 (3), 406-415, 2019 | 113 | 2019 |
